NO20090267L - Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse - Google Patents

Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse

Info

Publication number
NO20090267L
NO20090267L NO20090267A NO20090267A NO20090267L NO 20090267 L NO20090267 L NO 20090267L NO 20090267 A NO20090267 A NO 20090267A NO 20090267 A NO20090267 A NO 20090267A NO 20090267 L NO20090267 L NO 20090267L
Authority
NO
Norway
Prior art keywords
phenylmethyl
proline
oxo
amides
substituted
Prior art date
Application number
NO20090267A
Other languages
English (en)
Norwegian (no)
Inventor
Stefan Senger
Daryl Simon Walter
Laura Jane Chambers
Robert Gleave
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613473A external-priority patent/GB0613473D0/en
Priority claimed from GB0622825A external-priority patent/GB0622825D0/en
Priority claimed from GB0705263A external-priority patent/GB0705263D0/en
Priority claimed from GB0711439A external-priority patent/GB0711439D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20090267L publication Critical patent/NO20090267L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20090267A 2006-07-06 2009-01-16 Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse NO20090267L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0613473A GB0613473D0 (en) 2006-07-06 2006-07-06 Novel compounds
GB0622825A GB0622825D0 (en) 2006-11-15 2006-11-15 Novel compounds
GB0705263A GB0705263D0 (en) 2007-03-19 2007-03-19 Novel compounds
GB0711439A GB0711439D0 (en) 2007-06-13 2007-06-13 Novel receptor antagonists and their methods of use
PCT/EP2007/056675 WO2008003697A1 (en) 2006-07-06 2007-07-03 Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use

Publications (1)

Publication Number Publication Date
NO20090267L true NO20090267L (no) 2009-03-09

Family

ID=38508907

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090267A NO20090267L (no) 2006-07-06 2009-01-16 Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse

Country Status (26)

Country Link
US (2) US7718693B2 (ru)
EP (1) EP2049478B1 (ru)
JP (1) JP5283620B2 (ru)
KR (2) KR20140016431A (ru)
AR (1) AR061815A1 (ru)
AU (1) AU2007271182B2 (ru)
BR (1) BRPI0714062A2 (ru)
CA (1) CA2655675A1 (ru)
CR (2) CR10545A (ru)
CY (1) CY1113415T1 (ru)
DK (1) DK2049478T3 (ru)
EA (1) EA016076B1 (ru)
ES (1) ES2385505T3 (ru)
HK (1) HK1127604A1 (ru)
HR (1) HRP20120505T1 (ru)
IL (1) IL196181A0 (ru)
MA (1) MA30607B1 (ru)
MX (1) MX2009000117A (ru)
NO (1) NO20090267L (ru)
PE (1) PE20080997A1 (ru)
PL (1) PL2049478T3 (ru)
PT (1) PT2049478E (ru)
SI (1) SI2049478T1 (ru)
TW (1) TW200819127A (ru)
UA (1) UA100227C2 (ru)
WO (1) WO2008003697A1 (ru)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
ATE523499T1 (de) 2006-07-06 2011-09-15 Array Biopharma Inc Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
MX2009000117A (es) * 2006-07-06 2009-01-23 Glaxo Group Ltd N-fenilmetil-5-oxo-prolin-2-amidas sustituidas como antagonistas de receptores p2x7 y sus metodos de uso.
CA2656364C (en) 2006-07-06 2014-11-25 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
DE102006047617B4 (de) * 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
DE102006047619B4 (de) * 2006-10-09 2008-11-13 Clariant International Limited Verfahren zur Herstellung basischer Fettsäureamide
US9895242B2 (en) * 2006-10-22 2018-02-20 Idev Technologies, Inc. Secured strand end devices
GB0705882D0 (en) * 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
WO2008116845A1 (en) * 2007-03-28 2008-10-02 Glaxo Group Limited Piperidinone carboxamide derivatives as p2x7 modulators
EP2139875A2 (en) * 2007-03-29 2010-01-06 Glaxo Group Limited Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators
KR20090127435A (ko) * 2007-04-03 2009-12-11 글락소 그룹 리미티드 Ｐ2ｘ7 조절제로서의 이미다졸리딘 카르복스아미드 유도체
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
TWI450720B (zh) 2007-07-05 2014-09-01 Array Biopharma Inc 作為ａｋｔ蛋白質激酶抑制劑之嘧啶環戊烷
WO2009074518A1 (en) * 2007-12-12 2009-06-18 Glaxo Group Limited Combinations of prolinamide p2x7 modulators with further therapeutic agents
BRPI0822058A2 (pt) * 2007-12-18 2015-06-23 Glaxo Group Ltd Derivados de 5-oxo-3-pirrolidinacarboxamida como moduladores de p2x7
GB0724625D0 (en) * 2007-12-18 2008-01-30 Glaxo Group Ltd Novel compounds
ES2401685T3 (es) 2008-01-09 2013-04-23 Array Biopharma, Inc. Pirimidil ciclopentano hidroxilado como inhibidor de la proteína quinasa AKT
AU2009204025B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
GB0803729D0 (en) * 2008-02-29 2008-04-09 Ge Healthcare Ltd Imaging the central nervous system
ATE494926T1 (de) 2008-03-25 2011-01-15 Affectis Pharmaceuticals Ag Neuartige p2x7r-antagonisten und ihre verwendung
DE102008017216B4 (de) * 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
DE102008017219A1 (de) * 2008-04-04 2009-10-08 Clariant International Ltd. Verfahren zur Herstellung von Amiden in Gegenwart von überhitztem Wasser
DE102008017213B4 (de) * 2008-04-04 2012-08-09 Clariant International Limited Kontinuierliches Verfahren zur Herstellung von Amiden aliphatischer Hydroxycarbonsäuren
DE102008017218B4 (de) * 2008-04-04 2011-09-22 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden niederer aliphatischer Carbonsäuren
DE102008017214B4 (de) * 2008-04-04 2012-02-16 Clariant International Limited Kontinuierliches Verfahren zur Herstellung von Fettsäurealkanolamiden
DE102008017215B4 (de) * 2008-04-04 2012-08-09 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden ethylenisch ungesättigter Carbonsäuren
DE102008017217A1 (de) * 2008-04-04 2009-10-08 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Amiden aromatischer Carbonsäuren
US8629157B2 (en) 2009-01-05 2014-01-14 Boehringer Ingelheim International Gmbh Pyrrolidine compounds which modulate the CB2 receptor
MX2011010810A (es) 2009-04-14 2012-01-12 Affectis Pharmaceuticals Ag Nuevos antagonistas de p2x7r y su uso.
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
CA2783236C (en) * 2009-12-08 2020-03-10 Vanderbilt University Improved methods and compositions for vein harvest and autografting
US20130195919A1 (en) 2010-03-05 2013-08-01 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
EP2386541A1 (en) 2010-05-14 2011-11-16 Affectis Pharmaceuticals AG Novel methods for the preparation of P2X7R antagonists
DE102010056564A1 (de) 2010-12-30 2012-07-05 Clariant International Limited Hydroxylgruppen und Estergruppen tragende Polymere und Verfahren zu ihrer Herstellung
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
CN103402996B (zh) * 2011-01-04 2015-02-11 诺瓦提斯公司 可用于治疗年龄相关性黄斑变性(amd)的吲哚化合物或其类似物
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CA2828456C (en) * 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
CN103874689B (zh) 2011-04-01 2016-04-27 基因泰克公司 Akt抑制剂化合物和威罗菲尼的组合及使用方法
CN103841976A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ES2574840T3 (es) 2011-07-22 2016-06-22 Actelion Pharmaceuticals Ltd. Derivados de amidas heterocíclicas como antagonistas de receptores p2x7
PL2804865T3 (pl) 2012-01-20 2016-06-30 Idorsia Pharmaceuticals Ltd Heterocykliczne pochodne amidowe jako antagoniści receptora p2x7
US9075975B2 (en) * 2012-02-21 2015-07-07 Andrew Bud Online pseudonym verification and identity validation
CN104812749B (zh) 2012-12-12 2016-12-14 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物
JP6295270B2 (ja) 2012-12-18 2018-03-14 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしてのインドールカルボキサミド誘導体
JP6282016B2 (ja) 2013-01-22 2018-02-21 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
CA2897459C (en) 2013-01-22 2021-03-02 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
FR3026102A1 (fr) * 2014-09-19 2016-03-25 Univ Nice Sophia Antipolis Conjugues d'acide amine-pyridine/pyridinium et leurs utilisations en tant qu'agents biocides
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
KR102424709B1 (ko) 2016-05-31 2022-07-22 칼비스타 파마슈티컬즈 리미티드 혈장 칼리크레인 저해제로서 피라졸 유도체
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
DE102016111711A1 (de) * 2016-06-27 2017-12-28 Abb Schweiz Ag Installationsschaltgerät mit einem Gehäuse und mit einer Schraubanschlussklemme
EP3609868B1 (en) * 2017-03-13 2023-10-18 RaQualia Pharma Inc. Tetrahydroquinoline derivatives as p2x7 receptor antagonists
WO2019006074A1 (en) * 2017-06-28 2019-01-03 Indiana University Research And Technology Corporation PHARMACEUTICAL AGENT THAT RELATES TO THE P2X7 RECEIVER
HUE057912T2 (hu) 2017-11-29 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma kallikrein inhibitort tartalmazó dózisformák
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
WO2019185868A1 (en) * 2018-03-29 2019-10-03 Centre National De La Recherche Scientifique P2rx7 modulators in therapy
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
WO2021201680A1 (en) 2020-03-31 2021-10-07 Hasan Djohan Treatment of hyperinflammatory syndrome

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2651639A (en) * 1951-08-22 1953-09-08 American Cyanamid Co 2-pyrrolidone-5-carboxamide derivatives and methods of preparing the same
FR2273533A1 (fr) * 1974-06-04 1976-01-02 Ferlux Sa Nouveaux derives n-substitues d'acides pyrrolidones-2 carboxyliques-5
JPH0699307B2 (ja) 1987-08-20 1994-12-07 キッセイ薬品工業株式会社 抗痴呆剤
US4772601A (en) 1988-01-25 1988-09-20 Hoechst-Roussel Pharmaceuticals, Inc. 5-Substituted 1-(4-(1-pyrrolidinyl)-2-butynyl)-2-pyrrolidinones, pharmaceutical compositions and use
WO1997017958A1 (en) 1995-11-13 1997-05-22 Smithkline Beecham Corporation Hemoregulatory compounds
US6054579A (en) 1997-06-26 2000-04-25 Leukosite, Inc. Synthesis of substituted lactams
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
AU2160900A (en) 1998-12-11 2000-06-26 American Biogenetic Sciences, Inc. Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
CN1215028C (zh) 2002-05-24 2005-08-17 中国科学院上海有机化学研究所 外消旋的联二酚的光学拆分方法
US7288538B2 (en) * 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
EP2036548A1 (en) * 2003-09-22 2009-03-18 onepharm Research & Development GmbH Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
US20080021034A1 (en) * 2006-04-10 2008-01-24 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US20080076924A1 (en) * 2006-06-30 2008-03-27 Patrick Betschmann Piperazines as P2X7 antagonists
MX2009000117A (es) 2006-07-06 2009-01-23 Glaxo Group Ltd N-fenilmetil-5-oxo-prolin-2-amidas sustituidas como antagonistas de receptores p2x7 y sus metodos de uso.
DK2046740T3 (da) * 2006-07-22 2012-08-20 Oxagen Ltd Forbindelser med CRTH2-antagonistisk virkning
JP2010510987A (ja) * 2006-11-27 2010-04-08 ハー・ルンドベック・アクチエゼルスカベット ヘテロアリールアミド誘導体
DK2124562T3 (en) * 2007-03-09 2016-08-01 Second Genome Inc BICYCLOHETEROARYLFORBINDELSER AS P2X7 modulators and uses thereof
GB0705882D0 (en) * 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
WO2008116845A1 (en) * 2007-03-28 2008-10-02 Glaxo Group Limited Piperidinone carboxamide derivatives as p2x7 modulators
EP2139875A2 (en) * 2007-03-29 2010-01-06 Glaxo Group Limited Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators
KR20090127435A (ko) * 2007-04-03 2009-12-11 글락소 그룹 리미티드 Ｐ2ｘ7 조절제로서의 이미다졸리딘 카르복스아미드 유도체
BRPI0809567A2 (pt) * 2007-04-10 2014-09-23 Lundbeck & Co As H Composto, composição farmacêutica, método para modular a atividade de um receptor de p2x7, para tratar uma condição responsiva à modulação do receptor de p2x7 em um paciente, para inibir a morte de células do gânglio retinal em um paciente, e para determinar a presença ou ausência do receptor de p2x7 em uma amostra, preparação farmacêutica acondiciaonada, e, uso de um composto

Also Published As

Publication number Publication date
EA016076B1 (ru) 2012-01-30
PT2049478E (pt) 2012-07-16
PE20080997A1 (es) 2008-10-02
WO2008003697A1 (en) 2008-01-10
KR20140016431A (ko) 2014-02-07
AU2007271182B2 (en) 2012-03-15
JP2009542595A (ja) 2009-12-03
CR10545A (es) 2009-01-27
AR061815A1 (es) 2008-09-24
KR101398264B1 (ko) 2014-05-26
MA30607B1 (fr) 2009-07-01
US7718693B2 (en) 2010-05-18
EA200970085A1 (ru) 2009-06-30
DK2049478T3 (da) 2012-07-09
SI2049478T1 (sl) 2012-08-31
IL196181A0 (en) 2009-09-22
ES2385505T3 (es) 2012-07-25
HK1127604A1 (en) 2009-10-02
PL2049478T3 (pl) 2012-09-28
EP2049478B1 (en) 2012-05-30
JP5283620B2 (ja) 2013-09-04
KR20090028808A (ko) 2009-03-19
CA2655675A1 (en) 2008-01-10
US20080009541A1 (en) 2008-01-10
MX2009000117A (es) 2009-01-23
CY1113415T1 (el) 2016-06-22
US20100144829A1 (en) 2010-06-10
BRPI0714062A2 (pt) 2012-12-18
AU2007271182A1 (en) 2008-01-10
UA100227C2 (ru) 2012-12-10
CR20140515A (es) 2014-12-01
US8048907B2 (en) 2011-11-01
EP2049478A1 (en) 2009-04-22
HRP20120505T1 (hr) 2012-07-31
TW200819127A (en) 2008-05-01

Similar Documents

Publication Publication Date Title
NO20090267L (no) Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
ATE502017T1 (de) Pyrazolderivate als p2x7-modulatoren
NO20063449L (no) Substituerte heterocykler og deres anvendelse
ATE489088T1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid- derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
NO20070489L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
MX2009006540A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides.
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
NO20065678L (no) 3-(4-heteroarylcykloheksylamino) cyklopentankarboksamider som modulatorer for kjemokinreseptorer.
MY151246A (en) Benzofuranyl derivatives
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
NO20083567L (no) Hydantoinderivater for behandling av inflammatoriske forstyrrelser
NO20084363L (no) 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
MY153719A (en) Prokineticin 1 receptor antagonists
WO2007079163A3 (en) Prokineticin 1 receptor antagonists
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
WO2007053765A3 (en) Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application